PF-4950834

• Description :

  PF-4950834 is a potent, selective, orally bioavailable, ATP-competitive rho kinase inhibitor with IC50 values of 8.35 nM and 33.12 nM against ROCK2 and ROCK1, respectively. PF-4950834 inhibits neutrophil migration[1].

• UNSPSC :

  12352005

• Target :

  PKA; PKC; ROCK; SGK

• Type :

  Reference compound

• Related Pathways :

  Cell Cycle/DNA Damage; Cytoskeleton; Epigenetics; Metabolic Enzyme/Protease; Stem Cell/Wnt; TGF-beta/Smad

• Applications :

  COVID-19-anti-virus

• Field of Research :

  Inflammation/Immunology

• Assay Protocol :

  https://www.medchemexpress.com/pf-4950834.html

• Purity :

  99.60

• Solubility :

  10 mM in DMSO

• Smiles :

  O=C(NC)C1=CC=CC(CNC(C2=CC=C(C3=CC=NC=C3)C=C2)=O)=C1

• Molecular Formula :

  C21H19N3O2

• Molecular Weight :

  345.39

• References & Citations :

  [1]Rajagopalan LE, et al. Biochemical, cellular, and anti-inflammatory properties of a potent, selective, orally bioavailable benzamide inhibitor of Rho kinase activity. J Pharmacol Exp Ther. 2010 Jun;333 (3) :707-16.

• Shipping Conditions :

  Room Temperature

• Storage Conditions :

  4°C (Powder, sealed storage, away from moisture and light)

• Scientific Category :

  Reference compound1

• Clinical Information :

  No Development Reported

• Isoform :

  PKA; PKCη; ROCK1; ROCK2

• CAS Number :

  [1256264-62-6]